Bristol Myers Squibb Acquires RayzeBio for $4.1 Billion
On December 26, Bristol Myers Squibb (BMS) announced that it was entering a merger agreement to acquire RayzeBio, Inc. BMS will commence a tender offer to acquire all of the outstanding shares of RayzeBio common stock at a price of $62.50 per share in an all-cash transaction for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. RayzeBio is a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs. Current pipeline programs are targeting the treatment of solid tumors, including... Read More »
PE-Backed Laboratoire X.O Acquires nimodipine
Laboratoire X.O, backed by European mid-market private equity firm Stanley Capital Partners, announced on November 6 that it purchased nimodipine from Bayer AG, a German biopharmaceutical company. nimodipine is a second-generation calcium channel blocker designed to prevent and treat cerebral vasospasm following an aneurysmal subarachnoid hemorrhage. nimodipine is sold and marketed under the brand name Nimotop. Laboratoire X.O is a pharmaceutical company that specializes in mature market authorizations to sell and market drugs across various therapeutic areas such as pain, central nervous system, cardiology, oral care and women’s health. It is based in Paris, France. The... Read More »
TenX Keane Acquires Citius Pharmaceuticals
On October 24, TenX Keane Acquisition, a special purpose acquisition company (SPAC), announced that it entered into an agreement with Citius Pharmaceuticals, Inc. to acquire Citius’ oncology subsidiary. The transaction is valued at $675 million. Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products. The company has a pipeline of anti-infectives in adjunct cancer care, stem cell therapy and unique prescription products. According to Citius’ financial reports, it did not generate any revenues for both years ended September 30, 2022 and September 30,2021. TenX is led by... Read More »
Roche Acquires Telavant for $7.1 Billion
Roche Holding AG announced on October 23 that it will acquire Telavant Holdings from its majority owner, Roivant Sciences. Under the terms of the agreement, Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. Telavant is a biotechnology company that produces drugs to treat inflammatory and fibrotic diseases. It is in the process of developing a new therapy for patients with Crohn’s disease. Telavant was jointly formed by Roivant and Pfizer, Inc. in 2022 to develop and commercialize RVT-3101, a monthly subcutaneously administered anti-TL1A antibody, in the United States and Japan. Roivant currently owns 75% of the issued and... Read More »